NCT00262028

Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Children

A Phase 2, Randomized, Single-blind, Controlled, Single-Center Study to Compare the Safety and Immunogenicity of One Dose of Chiron Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Polysaccharide Vaccine Administered to Healthy Children 2-10 Years of Age and an Open-label Study to Assess the Safety and Immunogenicity of One Dose of Chiron Meningococcal ACWY Conjugate Vaccine Administered to Healthy Toddlers 12-23 Months of Age

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 910 (actual)
• Sponsor: Novartis Vaccines · Industry
• Sex: All
• Age: 12 Months – 10 Years
• Healthy volunteers: —

Summary

The purpose of this study is to evaluate the safety and immunogenicity of Novartis (formerly Chiron) Meningococcal ACWY Conjugate Vaccine administered to healthy children ages 1 - 10 years

Conditions

• Prevention of Meningococcal Disease

Interventions

Type	Name	Description
BIOLOGICAL	MenACWY-CRM Vaccine
BIOLOGICAL	MenACWY-PS Vaccine

Timeline

• Start date: 2005-04-01
• Primary completion: 2006-11-01
• Completion: 2006-11-01
• First posted: 2005-12-06
• Last updated: 2016-02-11
• Results posted: 2016-02-11

Locations

1 site across 1 country: United States